- Home
- ABP vs CLRB Comparison
ABP vs CLRB Comparison
Compare ABP & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABP | CLRB |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABP | CLRB |
|---|---|---|
| Price | $2.19 | $3.35 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.7K | ★ 127.6K |
| Earning Date | 04-02-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $2.00 | $2.45 |
| 52 Week High | $39.60 | $20.60 |
Technical Indicators
Market Signals| Indicator | ABP | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 26.52 | 47.32 |
| Support Level | $2.00 | $3.33 |
| Resistance Level | $3.33 | $3.98 |
| Average True Range (ATR) | 0.39 | 0.31 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 8.22 | 26.92 |
Price Performance
Historical ComparisonAbout ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.